BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion
- Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named…
Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss
Three-month interim data from first-of-its-kind trial demonstrate that the combination of Sculptra®…
Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Primary endpoint of DFS met at first prespecified interim analysis, showing a…
Pharming announces public cash offer to the shareholders of Abliva AB
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s…
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing…
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate…
Azerion publishes Interim Unaudited Financial Results Q3 2024 and Year to Date Q3 2024
Robust Platform performance driving growth Highlights of Q3 2024 In Q3 2024…
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
− Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown…
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
November 15, 2024 17:52 ET | Source: Protara Therapeutics NEW YORK, Nov.…